Why is a coagulation profile done in von Willebrand disease?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 6, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

A coagulation profile is crucial in von Willebrand disease to diagnose the condition, determine its type and severity, and guide treatment decisions, as it includes essential tests such as prothrombin time (PT), activated partial thromboplastin time (aPTT), von Willebrand factor antigen (VWF:Ag), von Willebrand factor ristocetin cofactor activity (VWF:RCo), and factor VIII coagulant activity (FVIII) 1.

Importance of Coagulation Profile in von Willebrand Disease

The coagulation profile is vital for identifying the presence of von Willebrand disease (vWD), differentiating it from other bleeding disorders, and classifying its type and severity. According to the 2008 NHLBI/NIH guidelines, the initial laboratory evaluation for vWD should include a complete blood count (CBC), prothrombin time (PT), and activated partial thromboplastin time (aPTT) 1. These tests help to suggest whether coagulation factor deficiency or thrombocytopenia might be the potential cause of clinical bleeding.

Key Components of the Coagulation Profile

The coagulation profile for vWD typically includes:

  • VWF antigen (VWF:Ag)
  • VWF ristocetin cofactor activity (VWF:RCo)
  • Factor VIII coagulant activity (FVIII) These tests are recommended for initial evaluation and can help establish the diagnosis, suggest the type and severity of vWD, and guide treatment decisions 1.

Interpretation of Test Results

The results of the coagulation profile can help differentiate between the three main types of vWD: Type 1 (partial quantitative deficiency), Type 2 (qualitative defects with several subtypes), and Type 3 (complete deficiency). The ratio of VWF:RCo to VWF:Ag is particularly useful in differentiating Type 1 from Type 2 1. Accurate diagnosis through coagulation testing is crucial because treatment approaches vary by type, from desmopressin (DDAVP) for milder cases to von Willebrand factor concentrates for more severe forms.

Monitoring and Treatment

Regular monitoring with coagulation profiles may also be necessary to assess treatment effectiveness and adjust management strategies over time. The initial coagulation profile serves as a baseline, and subsequent tests can help evaluate the response to treatment and guide adjustments to the treatment plan 1.

From the Research

Coagulation Profile in von Willebrand Disease

  • A coagulation profile is done in von Willebrand disease to assess the patient's bleeding tendency and to guide treatment decisions 2, 3, 4, 5, 6.
  • The coagulation profile typically includes tests such as bleeding time, activated partial thromboplastin time (aPTT), factor VIII activity, and von Willebrand factor (vWF) antigen and activity levels 2, 4.
  • These tests help to identify the type and severity of von Willebrand disease, which is essential for selecting the appropriate treatment strategy 3, 5.
  • The coagulation profile may also include tests to evaluate platelet function, such as platelet counts and platelet aggregation studies 2, 4.
  • Abnormalities in the coagulation profile can indicate a deficiency or dysfunction of vWF, which can lead to impaired platelet adhesion and aggregation, and increased bleeding risk 6.

Importance of Coagulation Profile

  • The coagulation profile is crucial in the diagnosis and management of von Willebrand disease, as it helps to identify patients who are at risk of bleeding complications 3, 5.
  • The results of the coagulation profile can guide the selection of treatment options, such as desmopressin or vWF:FVIII concentrates, and help to monitor the effectiveness of treatment 3, 5.
  • A coagulation profile can also help to identify patients who may require additional treatments, such as antifibrinolytic agents, to prevent bleeding complications during surgery or other invasive procedures 5.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Laboratory diagnosis of congenital von Willebrand disease.

Seminars in thrombosis and hemostasis, 2002

Research

Diagnosis and management of von Willebrand disease.

Haemophilia : the official journal of the World Federation of Hemophilia, 1999

Research

[Coagulation tests in von Willebrand's disease(author's transl)].

Deutsche medizinische Wochenschrift (1946), 1975

Research

Treatment of patients with von Willebrand disease.

Journal of blood medicine, 2011

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.